The FDA is working with the World Health Organization and foreign regulatory authorities to support an investigation into the source of contaminated cough syrups that have killed more than 300 children in Africa and Asia.
If you are not happy with the results below please do another search
50 search results for:
Datascope, a unit of Getinge, had recalled 4,454 therapeutic devices in December following a death and four serious injuries from their use.
The new test specifically targets the XBB.1.5 Omicron variant and will help researchers closely track the virus’s lineage and provide insights into the epidemiology and impact it has on public health.
To effectively promote your brand, it is important to have a message that stands out and a story that will capture the attention of your target audience. We have utilized oncology message benchmarks to study more than 30,000 interactions between oncologists and sales representatives for over 100 brands to understand what makes them tick.
The updated COVID-19 boosters from Pfizer Inc./BioNTech SE and Moderna helped prevent symptomatic infections against the new XBB-related subvariants, offering new evidence of how the vaccines perform against these fast-spreading strains, U.S. officials said today.
A biotech company focused on short-duration psychedelic-assisted therapies for mental health conditions announced positive top-line results from the first placebo-controlled efficacy study exploring a short-duration psychedelic for the treatment of major depressive disorder.
The enrollment is a jump of more than 12% over last year and the highest since the Affordable Care Act was signed 13 years ago, the U.S. government said today.
These are the first lawsuits of their kind since the U.S. Supreme Court overturned the federal constitutional right to abortion.
The multinational healthcare giant recorded overall medical device sales of $3.75 billion, missing analysts’ average estimate of $3.84 billion.
A group of 25 senators, led by Sen. Elizabeth Warren (D-MA), requested that HHS Sec. Xavier Becerra exercise march-in rights for Xtandi, a prostate cancer therapeutic. March-in rights give the government the right to take a license for itself if it helped to fund the product owner’s research.